WHAT IS CLAIMED IS:

1. Use of oxaliplatin and capecitabine in the manufacture of a medicament for treating gastric cancer or reducing viability of gastric cancer cells in a subject, wherein:

the oxaliplatin and capecitabine are to be administered to the subject; or the cancer cells, and

an alternating electric field is to be applied to a target region of the subject or the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz,

wherein at least a portion of the alternating electric field is to be applied simultaneously with the administration of oxaliplatin and capecitabine, or after administration of the oxaliplatin and capecitabine.

2. The use of claim 1, wherein at least a portion of the alternating electric field is to be applied after administration of the oxaliplatin and capecitabine and before the oxaliplatin and capecitabine are eliminated from the subject's body.

3. The use of claim 1, wherein the alternating electric field is to be applied for a duration of at least 72 hours.

4. The use of claim 1, wherein the frequency of the alternating electric field is between 120 and 180 kHz.

5. The use of claim 1, wherein the frequency of the alternating electric field is between 145 and 155 kHz.

6. The use of claim 1, wherein the oxaliplatin and capecitabine are to be administered at therapeutically effective doses, and the alternating electric field has a field strength of at least 1 V/cm in at least a portion of the target region.

7. The use of claim 6, wherein the alternating electric field is to be applied for a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 120 and 180 kHz.

8. The use of claim 6, wherein the alternating electric field is to be applied for a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 145 and 155 kHz.

9. The use of claim 1, wherein at least a portion of the alternating electric field is to be applied simultaneously with the administration of oxaliplatin and capecitabine.

10. The use of claim 1, wherein each of the oxaliplatin and capecitabine is to be delivered to the gastric cancer cells at a therapeutically effective concentration, and the alternating electric field has a field strength of at least 1 V/cm in at least some of the gastric cancer cells.

11. The use of claim 10, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 120 and 180 kHz.

12. The use of claim 10, wherein the alternating electric field is to be applied for a duration of at least 72 hours and the frequency of the alternating electric field is between 145 and 155 kHz.

13. The use of claim 1, wherein oxaliplatin and capecitabine are to be administered over a treatment cycle of 21 days.

14. The use of claim 13, wherein the oxaliplatin is to be administered on day 1 of the treatment cycle.

15. The use of claim 13, wherein the capecitabine is to be administered on day 1 to day 14 of the treatment cycle.

16. The use of claim 13, wherein the oxaliplatin and capecitabine are to be administered concurrently on day 1 of the treatment cycle.

17. The use of claim 1, wherein oxaliplatin is to be administered intravenously.

18. The use of claim 1, wherein capecitabine is to be administered orally.